Page 14 - SLIDES
P. 14
KEYNOTE 564: 12m adjuvant pembrolizumab vs placebo
ccRCC – high recurrence risk 496 498
pT2 (G4, sarcomatoid) 6.0% Pembrolizumab Placebo
pT≥3 91.3% 200mg IV q3wk q3wk
pTanyN+ 6.2%
Resected M1 NED 5.8% Median f/u 24.1m
1º outcome: DFS per investigator
NEJM 2021; 385:683-94
